Volitionrx (VNRX) Net Income towards Common Stockholders (2012 - 2026)

Volitionrx (VNRX) has 10 years of Net Income towards Common Stockholders data on file, last reported at $260595.0 in Q4 2025.

• Quarterly Net Income towards Common Stockholders rose 104.5% year-over-year to $260595.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$5.7 million (up 78.95% YoY) and the FY2025 annual result came in at $146302.0, up 100.54% from the prior year.
• Net Income towards Common Stockholders advanced to $260595.0 in Q4 2025, from -$31433.0 in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $260595.0 in Q4 2025 to a low of -$9.5 million in Q2 2023.
• A 5-year average of -$4.9 million and a median of -$6.5 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders plunged 88751.34% — and 2022, when it surged 791.1%.
• Tracing VNRX's Net Income towards Common Stockholders over 5 years: stood at -$8.0 million in 2021, then gained by 9.87% to -$7.2 million in 2022, then fell by 20.11% to -$8.7 million in 2023, then jumped by 33.4% to -$5.8 million in 2024, then soared by 104.5% to $260595.0 in 2025.
• The last three Net Income towards Common Stockholders figures came in at $260595.0 (Q4 2025), -$31433.0 (Q3 2025), and $29992.0 (Q2 2025), per Business Quant data.